Last reviewed · How we verify
NPO-13
At a glance
| Generic name | NPO-13 |
|---|---|
| Sponsor | Nihon Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase Ⅱ Dose Response Study of NPO-13 in Patients Undergoing Total Colonoscopy (PHASE2)
- Study of NPO-13 During Colonoscopy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NPO-13 CI brief — competitive landscape report
- NPO-13 updates RSS · CI watch RSS
- Nihon Pharmaceutical Co., Ltd portfolio CI